ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / LIMN / earnings
CRIS (27) PMCB (35) CELZ (20) BTTC (38) ⌘ Pro Terminal →

Liminatus Pharma Inc. (Class A) (LIMN) Next Earnings Date & Expected ±12.5% Move

$2.82 -2.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.80

Liminatus Pharma Inc. (Class A) (LIMN) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $3.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LIMN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LIMN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Liminatus Pharma Inc. (Class A) (NASDAQ: LIMN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $2.82 (-2.59% 1D, market cap $3.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LIMN ranks #734 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LIMN compare to CRIS and PMCB in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LIMN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRIS (Curis Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M) and PMCB (PharmaCyte Biotech Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -30.2%, cap $3.6M). Among the 5-stock peer group, LIMN leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LIMN?
▼

Per LIMN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001971387), Liminatus Pharma Inc. (Class A) generated $0 in revenue, -$10.2M in net income, and -$10.0M in free cash flow against $512.8K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.80 (-0.66%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (3)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.6% Base Target
$149 Bull$3 Base$2 Bear
📬 FREE LIMN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LIMN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY LIMN SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 37.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$3.45-9.9% Next Q
Q2 (-2Q)
39
Grade E$3.11+1.6% Next Q
Q3 (-1Q)
37
Grade E$3.16-10.8% Next Q
Current
34
Grade E$2.82-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LIMN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LIMN currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.61) and Max Pain ($2.96) forces dealer call-delta covering toward $148.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LIMN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LIMN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.35 Expected Swing
$2.47 (-12.5%)Spot $2.82$3.17 (+12.5%)
MODEL EARNINGS SETUP GAUGE

LIMN Quantitative Pre-Earnings Setup: 34/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (34/100)Model Risk Weight (66/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$0-$10.2M-$10.0M52%
FY 20242024-12-31$0-$3.5M-$1.5M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LIMN)

  • ✓Walkthrough of LIMN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LIMN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -73.52%🛡️ HOLDING TREND SUPPORT
2026-11-02O $2.92H $2.92L $2.82C $2.82VOL 28.8K
RES: $6.98SUP: $2.13SMA50: $3.61SMA200: $10.92
$80.34$59.31$38.28$17.25$-3.78RES $6.98SUP $2.13$2.822026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LIMN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LIMN Butterfly Map → + Track LIMN →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LIMN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LIMN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LIMN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LIMN)

Health Care Rank #734 of 1016 ⚔️ CRIS vs LIMN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LIMN vs. CRIS, PMCB, CELZ, BTTC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Liminatus Pharma Inc. (Class A) (LIMN) ranks #734 by composite RQD confidence (34/100, grade E) and #963 by equity capitalization ($3.9M). Within this direct 5-issuer industry benchmark cohort, LIMN leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with LIMN at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LIMN ACTIVE
Liminatus Pharma Inc. (Class A)
E 34/100 — — -35.0% -2.59% $3.9M Benchmark Subject
CRIS
Curis Inc.
E 27/100 — — -35.0% +9.39% $3.7M /cris-vs-limn →
PMCB
PharmaCyte Biotech Inc.
D- 35/100 — — -30.2% -9.03% $3.6M /pmcb-vs-limn →
CELZ
Creative Medical Technology Holdings Inc.
E 20/100 — 63.4% -35.0% -3.45% $5.2M /celz-vs-limn →
BTTC
Black Titan Corporation
D- 38/100 — — — -8.05% $5.3M /bttc-vs-limn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001971387

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Liminatus Pharma Inc. (Class A) (LIMN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$10.2M, operating cash flow of -$10.0M, and free cash flow of -$10.0M (-587.5% YoY). On the balance sheet, LIMN closed FY2025 with $512.8K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$10.2M -$10.0M -$10.0M $512.8K —
FY2024 (FY) 2024-12-31 $0 -$3.5M -$1.5M -$1.5M $5.4M —

3. LIMN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LIMN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Liminatus Pharma Inc. (Class A) (NASDAQ: LIMN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $2.82 (-2.59% 1D, market cap $3.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LIMN ranks #734 in composite RQD confidence.

How does LIMN compare to CRIS and PMCB in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LIMN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRIS (Curis Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M) and PMCB (PharmaCyte Biotech Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -30.2%, cap $3.6M). Among the 5-stock peer group, LIMN leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LIMN?

Per LIMN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001971387), Liminatus Pharma Inc. (Class A) generated $0 in revenue, -$10.2M in net income, and -$10.0M in free cash flow against $512.8K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LIMN trading relative to its 50-day, 200-day, and 52-week technical levels?

LIMN last traded at $2.82 (-2.59% on volume of 12,991 shares), positioning the stock -21.88% below its 50-day simple moving average ($3.61) and -74.18% below its 200-day simple moving average ($10.92). Across its 52-week range of $2.75 to $141.50, LIMN sits at the 0.1% percentile with a 14-day RSI of 37.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.47 to $3.17).

LIMN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is LIMN's next earnings date?

Based on SEC filing cadence, Liminatus Pharma Inc. (Class A) (LIMN)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is LIMN stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for LIMN, spanning a range between $2.47 and $3.17.

Direct Sub-Reports: LIMN RQD Cockpit LIMN 12M Forecast LIMN Earnings & Move LIMN Dividends & DRIP LIMN Insiders & 13F LIMN Whale Options LIMN Profit Sankey LIMN News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LIMN — Liminatus Pharma Inc. (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:53:45Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, LIMN carries an RQD Score of 34 out of 100, graded E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are scored as follows:

  • Fundamental Cash Engine: 7 / 20. Per the Roarable RQD rating, ROIC is -35% and FCF yield is 0%. For a prospective investor, this means the business is not currently generating returns on invested capital or free cash flow that would support the share price on an earnings or cash basis. Any valuation case must rest on future developments not reflected in current reported economics.
  • Whale 13F Flow: 3 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning, and it is the lowest-scoring pillar. Weak institutional flow means limited professional sponsorship, which typically translates into thinner liquidity and fewer natural buyers during periods of stress.
  • Insider Conviction: 5 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. A low score indicates insider and disclosed-trade signals provide little evidence of conviction behind the stock.
  • Macro Regime Fit: 9 / 20. Per the Roarable RQD rating, beta is 1.0 and the pillar reflects sector sensitivity. The stock's market sensitivity is not extreme, but the pillar score indicates limited alignment with the prevailing macro regime.
  • Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 1/9, and Debt/Equity is 0.5. The Piotroski reading in particular signals weak financial-quality indicators, and the balance sheet is a notable source of risk.

Investor implications. The upside case would depend on a future inflection in cash generation or a strengthening of institutional and insider sponsorship, neither of which is evidenced in current data. The valuation tradeoff is stark: with market capitalization of $3.9M and no positive cash return, the stock's price is not anchored to current earnings or cash flow. Forensic risk indicators point to elevated downside uncertainty. This analysis is educational and not personalized financial advice.

Business

Liminatus Pharma Inc. (Class A) (LIMN) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company has a market capitalization of $0.0B. Not available in source data: specific products, customers, or revenue model descriptions.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025 (filed 2025-12-31)$0.0M$-3.0M$-10.2MN/A$-10.0MN/AN/A
FY 2024 (filed 2024-12-31)$0.0M$-3.3M$-3.5MN/A$-1.5MN/AN/A

Per the SEC financials, reported revenue was $0.0M in both periods, with operating losses of $-3.0M (FY 2025) and $-3.3M (FY 2024) and net losses of $-10.2M and $-3.5M respectively. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9. Per the Roarable RQD rating, Debt/Equity is 0.5; the balance sheet cash and debt figures are not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news feed, five items were published within roughly the prior 15 hours, all tagged to LIMN and all flagged YELLOW (MARKET WIRE): a TradingView estimates report, a Yahoo! Finance Canada item (headline referencing ATYR seasonal returns), a Yahoo Finance Australia quote page (headline referencing CDT Equity), a report referencing LIMNW trading near $0.04, a Yahoo Finance Singapore quote page (CDT Equity), and a Yahoo Finance Australia quote page (Adlai Nortye, ANL). These items are generic market-data pages; none describes a specific fundamental catalyst. Per the Butterfly Supply-Chain Graph, no proprietary signals or supply-chain links are recorded. Risk watch items include the 52-week range of $2.75 to $141.5, indicating a severe historical price decline, and a -0.86% change on the day.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain status is NONE and there are no butterfly links. Not available in source data: upstream suppliers, downstream customers, and sector correlation mappings. Investors should note that the 52-week range and the presence of a warrant-related reference (LIMNW) in the news feed are the only ripple-type observations available, and neither is resolved by the source data.

Open Questions

  • What products or therapies does Liminatus develop, and what is the stage of its clinical or regulatory pipeline?
  • What explains the drop from a 52-week high of $141.5 to a current price of $2.9, and is there a reverse split or capital event involved?
  • What are the cash and debt balances behind the reported operating and net losses?
  • Does the company have a funding runway that covers its annual cash burn of $-10.0M in FY 2025?
  • Why are per-share metrics such as EPS and P/E unavailable, and what share count underlies the $3.9M market capitalization?

LIMN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Liminatus Pharma Inc. (Class A) (LIMN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LIMN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LIMN Bull vs. Bear Conversation Board — What's Your Call at $2.82?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LIMN 🐻 67% BEARISH CONVICTION
1. Pick Your Side on LIMN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.55 (-12.1%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is LIMN (E • RQD 34/100) a Buy at $2.90?

Welcome to the LIMN (Liminatus Pharma Inc. (Class A)) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.20 (-24.1%)
Spot @ $2.90

Pump the brakes on LIMN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on LIMN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Liminatus Pharma Inc. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.39 (+16.9%)
Spot @ $2.90

LIMN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on LIMN, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $2.90 (52-wk range $2.75 - $141.50), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%